Publicis Groupe agencies including BBH, Digitias and Publicis Sapient went through a round of layoffs earlier this month.

Doctors say string missed jugular vein but left deep cuts The post In Rawalpindi, kite string slits minor’s throat appeared first on The Express Tribune.

Singapore's Sentosa Island has virtually cut the ribbon on its latest marketing efforts, Sentosa Crossing, a digital replica of the Little Red Dot's southern recreational destination on Nintendo Switch's Animal Crossing: New Horizons.As the coronavirus contin…

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.

Brett Edgar is leaving her post as managing director of BBH New York to join 72andSunny. This summer, Edgar will become president of 72andSunny's New York office, a role that's been empty since Jess Monsey left earlier this year to join Wieden + Kennedy Portl…

Yahoo Finance's Seana Smith and ETF Trends CIO and Director Dave Nadig discuss the outlook on biotech ETFs as optimism grows over results for coronavirus treatments.

Virus cases rise amid concerns about medical capacity The post Lockdown relaxation leaves govt anxious appeared first on The Express Tribune.

The executives performed the evergreen Louis Armstrong hit 'What A Wonderful World!' from their homes as the lockdown in India begins easing.

In a statement, CEO Neil Munn said the agency is "restructuring our business in line with the new realities."

While all eyes are on the fate of the phase one trade deal between the United States and China, Healthcare sector can forget tension and soar higher in 2020 even if there is no deal.

The shop is the first Publicis Groupe agency to confirm layoffs related to the coronavirus pandemic.

The S&P 500 is down 10.8% this year, after a massive recovery in April. But these ETF areas have beaten the S&P 500 this year.

Midweek ad news roundup.

Here is a look at the 25 best and 25 worst ETFs from the past trading month. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby serving as potential starting points for those looking to take on either short or long positions. Likewise, traders can also use this list to spot potential trend reversal opportunities that may offer a generous risk/reward. As always, investors of all experience levels are advised to use stop-loss orders and practice disciplined profit-taking techniques. To get access to all ETFdb.com premium content, sign up for a free 14-day trial to ETFdb.com Pro.

As the Covid-19-imposed lockdown rumbles on, there has never been a better time to invest in sex tech, according to Make Love Not Porn founder Cindy Gallop. The former chair of BBH New York says her user-generated, crowdsourced video-sharing platform — which …

To understand the extent to which ancestral functions are retained among duplicated genes, this study systematically swaps hundreds of essential yeast genes with their human orthologs from expanded gene families. The results reveal widespread differential rep…

BBH, HFH deliver test results within 12 hours The post Two BSL-3 labs expedite Covid-19 detection appeared first on The Express Tribune.

Rising investor interest in coronavirus related stocks will benefit these ETFs

Do you want to find the next Apple (NASDAQ:AAPL) or Amazon (NASDAQ:AMZN)? My advice is that you should set your sights lower, not higher and put some cash to work in three down, but not out heavyweight biotech stocks for the next big thing in investing. Let me explain.It has been a good week so far for the broader markets. The Nasdaq Composite, S&P 500 and Dow Jones Industrial Average have broken out of short bases barely discernible on the weekly chart and back within spitting distance of their respective all-time-highs following May's abrupt correction. It has been a nice period for biotech stocks as well.The Vaneck Vectors Biotech ETF (NYSEARCA:BBH) is up nearly 3.50% through Tuesday's close compared to gains of roughly 1% to 2% for the broader averages. But as any investor with a passing interest in the markets knows, the outperformance in biotech stocks has been anything but a recurring theme these past couple years.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer The good news is markets are cyclical. Even legendary investments such as AMZN or the sacrosanct AAPL stock have been known to correct for periods lasting not weeks, but months and even years. With that in mind, it's time to consider adding these three large-cap biotech stocks into your portfolio. Amgen (AMGN) Click to EnlargeAmgen (NASDAQ:AMGN) is a biotech heavyweight that also happens to be the sector's largest capitalization outfit with a valuation of about $110 billion.Following a recent sales and earnings beat, this reasonably-priced biotech giant, which pays investors nearly 3.5% in quarterly dividends, has now put together a bottom on the monthly price chart.Specifically, AMGN stock has formed a confirmed pivot low, which reaffirms its longstanding uptrend after a correction of several months. And with plenty of lateral, angular and Fibonacci price supports, as well as an oversold crossover signal to confirm the bottom, this biotech stock is a buy today.The TradeBuy AMGN stock at current prices. Set a stop-loss beneath support below $160, but expect shares to hit new highs in 2019's second half. Gilead Sciences (GILD) Click to EnlargeIt has been a rough few years for Gilead Sciences (NASDAQ:GILD), one the sector's largest names, but things are looking up for GILD stock lately.A recent earnings report that reiterated the company's full-year guidance and offered a modest year-over-year uptick in sales and profits looks promising for Gilead shares, which have been absolutely pummeled over the last four years.Technically, shares are trading slightly above multiple inside candlesticks following a double bottom pattern of about one and a half years. With the formation finding support off the 50% retracement level and a supportive-looking stochastics set-up signaling better months and years ahead, GILD stock looks good to buy right now. * 10 'Buy-and-Hold' Stocks to Own Forever The TradeBuy GILD stock at current levels with an initial stop-loss below $59. On the upside, $85 - $90 looks like a good area for profit-taking while allowing this down-and-out value stock some room to run. Biogen (BIIB) Click to EnlargeMuch like GILD stock, shares of sector heavyweight Biogen (NASDAQ:BIIB) have been under extreme technical duress the past few years.Most recently, the pain in BIIB stock came after the company's announcement that it was axing a drug to treat Alzheimer's following poor results. The suffering came despite the fact that BIIB posted stronger-than-forecast results in late April.On the price chart, this biotech stock's technical beating since 2015 has resulted in a possible four-year long double-bottom pattern that's finding support in-between the 50% and 62% retracement levels. Coupled with an oversold stochastics that is a hair's breadth away from signaling a bullish crossover, confirmation of the pivot low looks imminent.The TradeBuy BIIB stock above May's candle high of $238.17 to confirm the pattern bottom. I'd suggest an initial stop beneath $214 and to take partial profits in-between $300 - $310.Disclosure: Investment accounts under Christopher Tyler's management currently do not own positions in any of the securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 Compare Brokers The post 3 Large-Cap Biotech Stocks to Buy for Massive Gains appeared first on InvestorPlace.

Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

The global market has been rallying hard since October. Investors can thus bet on these high-flying ETFs.

As ETF investing constantly climbs the popularity charts, we highlight a few good ETF areas that investors can bank on for 2020.

AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.

Read attributed his departure to the holding company's new strategy of strengthening individual agency brands.

This evening, Tribeca Film Festival took to Instagram Live to announce the Jury-selected winning titles from the 19th annual confab, which was forced to postpone its originally scheduled April gathering in response to the global health crisis. Top honors went…

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.

This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.

It is less likely that Santa alone will drive Wall Street this season as trade tensions persist. Overall, these ETF investing trends should stay strong.

Biotech companies use or modify biological processes usually in order to create new pharmaceuticals or therapies. The biotech sector, is particularly hot right now as biotech companies around the world work diligently to discover and create potential vaccines and treatments related to the COVID-19 pandemic.

Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.

Despite the age-old trend of a Santa rally, 2018 was a massive downer. Since 2019 is giving the same cues, investors can seek refuge in these safer ETFs.

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

Publicis Communications East also rolled the capabilities of Second Story and Rokkan into Razorfish, resulting in the elimination of some positions.

Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

The question of priorities has long complicated how ESG investing is viewed across generations: detractors warn that the full potential of profits is almost always sacrificed to do good; proponents say that’s nothing but a myth.

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

Biotech ETFs are among the most popular investment vehicles. Here are some reasons for why they're worth considering.

Attendants asked to purchase injections themselves The post Pindi hospitals run short of dog bite vaccine appeared first on The Express Tribune.